Disease Modification Strategies and Unmet Needs in Myelofibrosis

Panelists discuss approved and emerging therapies for myelofibrosis, focusing on how these treatments aim to modify the disease and improve patient outcomes.

EP: 1.Myelofibrosis: Background, Risk Stratification, and Treatment Decision-Making

EP: 2.Approved and Investigational Agents for Myelofibrosis

Now Viewing

EP: 3.Disease Modification Strategies and Unmet Needs in Myelofibrosis

EP: 4.MANIFEST-2: Pelabresib in Myelofibrosis: MOA, Study Design, and Spleen Volume Reduction

EP: 5.Disease- Modifying Biomarker Data in the MANIFEST-2 Study Investigating Pelabresib

EP: 6.Safety Profile of the Pelabresib and Ruxolitinib Combination in Myelofibrosis

EP: 7.Pelabresib in MPNs: Immune Profiles of Responders vs. Non-responders

Recent Videos